[Skip to Content]
[Skip to Content Landing]

Year

Day

November 7, 2019
Original Investigation

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial

Abstract Full Text
open access
JAMA Oncol. Published online November 7, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.3848

This open-label, phase 1/2a study evaluates the safety and activity of fully human glucocorticoid-induced tumor necrosis factor (TNF) receptor–related protein agonist immunoglobulin G1 monoclonal antibody BMS-986156 with or without nivolumab in patients with advanced solid tumors.

Communication With Older Patients With Cancer Using Geriatric Assessment: A Cluster-Randomized Clinical Trial From the National Cancer Institute Community Oncology Research Program

Abstract Full Text
open access
JAMA Oncol. Published online November 7, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.4728

This cluster-randomized clinical trial examines whether providing a geriatric assessment summary and geriatric assessment–guided recommendations to oncologists can improve communication about aging-related concerns.

Research Letter

Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017

Abstract Full Text
JAMA Oncol. Published online November 7, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.4906

This cross-sectional study weighs the proportional associations of rising drug costs and use with increased Medicare Part D spending for a cohort of oral anticancer drugs used from 2013 through 2017.

Review

Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review

Abstract Full Text
JAMA Oncol. Published online November 7, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.3869

This review describes the development and use of axicabtagene ciloleucel for treatment in patients with refractory large B-cell lymphoma.

Viewpoint

Neuroendocrine Tumors—Less Well Known, Often Misunderstood, and Rapidly Growing in Incidence

Abstract Full Text
JAMA Oncol. Published online November 7, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.4568

This Viewpoint advocates for additional awareness and allocation of resources to address the increasing incidence of neuroendocrine tumors.

Invited Commentary

Expanding the Scope of Geriatric Assessment for the Management of Cancer in Older Adults

Abstract Full Text
JAMA Oncol. Published online November 7, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.4708
Poetry and Oncology

A Resident’s Courage

Abstract Full Text
JAMA Oncol. Published online November 7, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.4741
Comment & Response

Defining Equity in Eligibility for Cancer Screening

Abstract Full Text
JAMA Oncol. Published online November 7, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.4598

Defining Equity in Eligibility for Cancer Screening—Reply

Abstract Full Text
JAMA Oncol. Published online November 7, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.4604
×